Affimed N.V. (NASDAQ:AFMD) declined after announcing clinical data update on lead product candidate AFM13 in CD30+ lymphoma at the ICML 2019.

Affimed N.V. (NASDAQ:AFMD), a Healthcare sector firm, traded 1.87 Million shares in last trading session with closing price of $2.91 per share. Company return on investment (ROI) is -43.50%. Stock value has moved between $1.4 – 7.28 in last one year. Analyst’s mean target price for Affimed N.V. (NASDAQ:AFMD) is $8.17 while analysts mean recommendation is 1.50. AFMD EPS growth this year is 53.40%.



On last trading day, LogicBio Therapeutics, Inc. (NASDAQ:LOGC) shares closed at $13.06 per share. LOGC market capitalization is 282.75. Analyst’s mean target price for LogicBio Therapeutics, Inc. (NASDAQ:LOGC) is $22.25 whereas analysts mean recommendation is 1.60. Its weekly performance is -6.25% while year to date (YTD) performance is 25.58%.



In last session Mustang Bio, Inc. (NASDAQ:MBIO) traded 664146 shares and was closed at $3.54. Analyst’s mean target price for MBIO is $19.50 while analysts mean recommendation is 1.00. Company is -65.29% away from its 52 week high and is moving 62.39% ahead of its 52 week low. Mustang Bio, Inc. (NASDAQ:MBIO) quarterly performance is -1.12%.



Clovis Oncology, Inc. (NASDAQ:CLVS), a Healthcare sector firm, traded 3.12 Million shares on last trading day with closing price of $13.34 per share. Company gross margin stands at 79.20% whereas its return on investment (ROI) is -50.10%. Stock value has moved between $11.5 – 49.41 in last one year. Analyst’s mean target price for Clovis Oncology, Inc. (NASDAQ:CLVS) is $29.50 while analysts mean recommendation is 2.10. CLVS EPS growth this year is -80.50%.

